companies / apmonia-therapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 7,620,0007.6M | ○ |
|---|---|---|
| founded | 2019 | |
| hq | Reims, France | |
| industry | unknown | |
| stage | null |
Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment, with lead candidate AP-01 (TAX2) blocking TSP-1 binding to CD47. The Reims-based biotech serves patients with glioblastoma, ovarian, colorectal, and pancreatic cancer. Its peptide approach offers an alternative to other CD47 blockers while modulating.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-09-01 | grant | 2,700,0002.7M | null | ○ |
PHP 8.4, WordPress 6.9.4, Twenty Seventeen, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.8, DoubleClick Floodlight, Contact Form 7 6.1.6, CookieYes 3.4.2
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |